Abstract
Transmissible spongiform encephalopathies (TSEs) are prion protein misfolding diseases that involve the accumulation of an abnormal β-sheet-rich prion protein aggregated form (PrPsc) of the normal α- helix-rich prion protein (PrPc) within the central nervous system (CNS) and other organs. On account of its large size and insolubility properties, characterization of PrPc is quite difficult. A soluble intermediate, called PrPβ or βo, exhibiting many of the same features as PrPsc, can be generated using a combination of low pH and/or mild denaturing conditions. Here, we review the current knowledge on the following five issues relevant to the conversion mechanisms of PrPc to PrPsc : (1) How is the Stability of the Helical Structures in the Native PrPc Related to the Primary Structure of the PrPc (2) Why the Low pH Solution System is a Ideal Trigger of PrPc to PrPsc Conversion (3) How are the Structural and Dynamical Characteristics of the α-helixrich Intermediates Determined using NMR Data (4) How are the Premolten (PrPα4 and PrPαβ) and β-Oligomer (PrPβ) Intermediates Detected and Assayed, and (5) Can the Disordered N-terminal Domain be folded into the Structural Segment? Particularly, Chou’s wenxiang diagram (http://en.wikipedia.org/wiki/Wenxiang_diagram) was introduced for providing an intuitive picture. This review may help to further understand the prion protein misfolding mechanism.
Keywords: PrP, protein misfolding, NMR spectroscopy, CD, β-oligomer, premolten globule state, salt-bridge network, Chou’s wenxiang diagram.
Current Topics in Medicinal Chemistry
Title:The pH-Triggered Conversion of the PrPc to PrPsc
Volume: 13 Issue: 10
Author(s): Guo-Ping Zhou and Ri-Bo Huang
Affiliation:
Keywords: PrP, protein misfolding, NMR spectroscopy, CD, β-oligomer, premolten globule state, salt-bridge network, Chou’s wenxiang diagram.
Abstract: Transmissible spongiform encephalopathies (TSEs) are prion protein misfolding diseases that involve the accumulation of an abnormal β-sheet-rich prion protein aggregated form (PrPsc) of the normal α- helix-rich prion protein (PrPc) within the central nervous system (CNS) and other organs. On account of its large size and insolubility properties, characterization of PrPc is quite difficult. A soluble intermediate, called PrPβ or βo, exhibiting many of the same features as PrPsc, can be generated using a combination of low pH and/or mild denaturing conditions. Here, we review the current knowledge on the following five issues relevant to the conversion mechanisms of PrPc to PrPsc : (1) How is the Stability of the Helical Structures in the Native PrPc Related to the Primary Structure of the PrPc (2) Why the Low pH Solution System is a Ideal Trigger of PrPc to PrPsc Conversion (3) How are the Structural and Dynamical Characteristics of the α-helixrich Intermediates Determined using NMR Data (4) How are the Premolten (PrPα4 and PrPαβ) and β-Oligomer (PrPβ) Intermediates Detected and Assayed, and (5) Can the Disordered N-terminal Domain be folded into the Structural Segment? Particularly, Chou’s wenxiang diagram (http://en.wikipedia.org/wiki/Wenxiang_diagram) was introduced for providing an intuitive picture. This review may help to further understand the prion protein misfolding mechanism.
Export Options
About this article
Cite this article as:
Zhou Guo-Ping and Huang Ri-Bo, The pH-Triggered Conversion of the PrPc to PrPsc, Current Topics in Medicinal Chemistry 2013; 13 (10) . https://dx.doi.org/10.2174/15680266113139990003
DOI https://dx.doi.org/10.2174/15680266113139990003 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Associate Editor
Central Nervous System Agents in Medicinal Chemistry Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Lung Cancer Epidemiology - A Global View
Current Respiratory Medicine Reviews Quantitative Characterization of Phenotypical Markers After Differentiation of SH-SY5Y Cells
CNS & Neurological Disorders - Drug Targets Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews Review on Pharmacological and Phytochemical Prospects of Traditional Medicinal Plant: <i>Persicaria hydropiper</i> (Smartweed)
Current Topics in Medicinal Chemistry Biologic and Novel Therapy of the Inflammatory Bowel Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimers Disease: Therapeutic Implications
Current Drug Targets - CNS & Neurological Disorders Designing Multi-Targeted Therapeutics for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Development and Validation of a Liquid-Liquid Extraction and Gas Chromatography/Mass Spectrometry Methodology for Cannabidiol Analysis in Human Plasma
Current Pharmaceutical Analysis Triiodothyronine (T3) Effects on Cardiovascular System in Patients with Heart Failure
Recent Patents on Cardiovascular Drug Discovery Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry The Association Between Alcohol Use and the Progression of Alzheimer’s Disease
Current Alzheimer Research Receptor-Independent Effects of Endocannabinoids on Ion Channels
Current Pharmaceutical Design Therapeutic and Mechanistic Effects of Curcumin in Huntington’s Disease
Current Neuropharmacology Editorial [Research on Photocatalytic Properties and Degradation Mechanisms of Organics (Guest Editor: Jingfei Luan)]
Current Organic Chemistry Current Directions in Non-Invasive Low Intensity Electric Brain Stimulation for Depressive Disorder
CNS & Neurological Disorders - Drug Targets ACKNOWLEDGEMENTS TO REVIEWERS
Current Alzheimer Research Physiological Roles of Glycogen Synthase Kinase-3: Potential as a Therapeutic Target for Diabetes and Other Disorders
Current Drug Targets - Immune, Endocrine & Metabolic Disorders